Federal Register / Vol. 69, No. 23 / Wednesday, February 4, 2004 / Notices 5355

Emphasis Panel, Review of Conference 

Grants (R13s). 

Date: March 16, 2004. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS/National Institutes of Health, 

Building 4401, East Campus, 79 T.W. 

Alexander Drive, EC 122, Research Triangle 

Park, NC 27709 (Telephone conference call). 

Contact Person: RoseAnne M. McGee, 

Associate Scientific Review Administrator, 

Scientific Review Branch, Office of Program 

Operations, Division of Extramural Research 

and Training, Nat. Inst. of Environmental 

Health Sciences, P.O. Box 12233, MD EC–30, 

Research Triangle Park, NC 27709. 919–541–

0752.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS)

Dated: January 28, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–2367 Filed 2–3–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Review of Conference 

Grants (R13a). 

Date: March 16, 2004. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS/National Institutes of Health, 

Building 4401, East Campus, 79 T.W. 

Alexander Drive, EC 122, Research Triangle 

Park, NC 27709 (Telephone conference call). 

Contact Person: RoseAnne M. McGee, 

Associate Scientific Review Administrator, 

Scientific Review Branch, Office of Program 

Operations, Division of Extramural Research 

and Training, Nat. Inst. of Environmental 

Health Sciences, P.O. Box 12233, MD EC–30, 

Research Triangle Park, NC 27709. 919–541–

0752.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 92.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS)

Dated: January 28, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–2368 Filed 2–3–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines) 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

revised in the Federal Register on June 

9, 1994 (59 FR 29908) and on September 

30, 1997 (62 FR 51118). A notice listing 

all currently certified laboratories is 

published in the Federal Register

during the first week of each month. If 

any laboratory’s certification is 

suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

HHS’ National Laboratory Certification 

Program (NLCP) during the past month, 

it will be listed at the end, and will be 

omitted from the monthly listing 

thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov

and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 5600 

Fishers Lane, Rockwall 2, Room 815, 

Rockville, Maryland 20857; 301–443–

6014 (voice), 301–443–3031 (fax).

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines, 

‘‘Certification of Laboratories Engaged 

in Urine Drug Testing for Federal 

Agencies,’’ sets strict standards that 

laboratories must meet in order to 

conduct urine drug testing for Federal 

agencies. To become certified, an 

applicant laboratory must undergo three 

rounds of performance testing plus an 

on-site inspection. 

To maintain that certification, a 

laboratory must participate in a 

quarterly performance testing program 

plus periodic, on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements expressed in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines, the following 

laboratories meet the minimum 

standards set forth in the Mandatory 

Guidelines:

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328–

7840 / 800–877–7016, (Formerly: 

Bayshore Clinical Laboratory) 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770 / 888–290–

1150 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615–

255–2400 

Alliance Laboratory Services, 3200 

Burnet Ave., Cincinnati, OH 45229, 

513–585–6870, (Formerly: Jewish 

Hospital of Cincinnati, Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783,

5356 Federal Register / Vol. 69, No. 23 / Wednesday, February 4, 2004 / Notices 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT certify 

the laboratory (Federal Register, July 16, 1996) as 

meeting the minimum standards of the Mandatory 

Guidelines published in the Federal Register on 

June 9, 1994 (59 FR 29908) and on September 30, 

1997 (62 FR 51118). After receiving DOT 

certification, the laboratory will be included in the 

monthly list of HHS certified laboratories and 

participate in the NLCP certification maintenance 

program.

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center) 

Clinical Reference Lab, 8433 Quivira 

Rd., Lenexa, KS 66215–2802, 800–

445–6917 

Diagnostic Services Inc., dba DSI, 12700 

Westlinks Dr., Fort Myers, FL 33913, 

239–561–8200 / 800–735–5416 

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC 1229 

Madison St., Suite 500, Nordstrom 

Medical Tower, Seattle, WA 98104, 

206–386–2661 / 800–898–0180, 

(Formerly: Laboratory of Pathology of 

Seattle, Inc., DrugProof, Division of 

Laboratory of Pathology of Seattle, 

Inc.) 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Rd., Warminster, PA 18974, 

215–674–9310

Dynacare Kasper Medical Laboratories *, 

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, 780–451–

3702/800–661–9876

ElSohly Laboratories, Inc., 5 Industrial 

Park Dr., Oxford, MS 38655, 662–236–

2609

Express Analytical Labs, 3405 7th Ave., 

Suite 106, Marion, IA 52302, 319–

377–0500

Gamma-Dynacare Medical 

Laboratories *, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall St., 

London, ONT, Canada N6A 1P4, 519–

679–1630

General Medical Laboratories, 36 South 

Brooks St., Madison, WI 53715, 608–

267–6225

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823, (Formerly: 

Laboratory Specialists, Inc.) 

LabOne, Inc., 10101 Renner Blvd., 

Lenexa, KS 66219, 913–888–3927/

800–873–8845, (Formerly: Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Rd., 

Houston, TX 77040, 713–856–8288/

800–800–2387

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Dr., 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 10788 Roselle St., San 

Diego, CA 92121, 800–882–7272, 

(Formerly: Poisonlab, Inc.) 

Laboratory Corporation of America 

Holdings, 1120 Stateline Rd. West, 

Southaven, MS 38671, 866–827–8042/

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

Marshfield Laboratories, Forensic 

Toxicology Laboratory, 1000 North 

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734

MAXXAM Analytics Inc. *, 5540 

McAdam Rd., Mississauga, ON, 

Canada L4Z 1P1, 905–890–2555, 

(Formerly: NOVAMANN (Ontario) 

Inc.) 

MedTox Laboratories, Inc., 402 W. 

County Rd. D, St. Paul, MN 55112, 

651–636–7466/800–832–3244

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Dr., 

Minneapolis, MN 55417, 612–725–

2088

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515

Northwest Drug Testing, a division of 

NWT Inc., 1141 E. 3900 S., Salt Lake 

City, UT 84124, 801–293–2300/800–

322–3361, (Formerly: NWT Drug 

Testing, NorthWest Toxicology, Inc.) 

One Source Toxicology Laboratory, Inc., 

1705 Center St., Deer Park, TX 77536, 

713–920–2559, (Formerly: University 

of Texas Medical Branch, Clinical 

Chemistry Division; UTMB PathologyToxicology Laboratory) 

Oregon Medical Laboratories, P.O. Box 

972, 722 East 11th Ave., Eugene, OR 

97440–0972, 541–687–2134

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/

800–541–7891 x8991

PharmChem Laboratories, Inc., 4600 N. 

Beach, Haltom City, TX 76137, 817–

605–5300, (Formerly: PharmChem 

Laboratories, Inc., Texas Division; 

Harris Medical Laboratory) 

Physicians Reference Laboratory, 7800 

West 110th St., Overland Park, KS 

66210, 913–339–0372/800–821–3627

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340, 

770–452–1590/800–729–6432, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

Quest Diagnostics Incorporated, 4770 

Regent Blvd., Irving, TX 75063, 800–

824–6152, (Moved from the Dallas 

location on 03/31/01; Formerly: 

SmithKline Beecham Clinical 

Laboratories; SmithKline Bio-Science 

Laboratories) 

Quest Diagnostics Incorporated, 4230 

South Burnham Ave., Suite 250, Las 

Vegas, NV 89119–5412, 702–733–

7866/800–433–2750, (Formerly: 

Associated Pathologists Laboratories, 

Inc.) 

Quest Diagnostics Incorporated, 400 

Egypt Rd., Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

Quest Diagnostics Incorporated, 506 E. 

State Pkwy., Schaumburg, IL 60173, 

800–669–6995/847–885–2010, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; International 

Toxicology Laboratories) 

Quest Diagnostics Incorporated, 7600 

Tyrone Ave., Van Nuys, CA 91405, 

818–989–2520/800–877–2520, 

(Formerly: SmithKline Beecham 

Clinical Laboratories) 

Scientific Testing Laboratories, Inc., 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130

Sciteck Clinical Laboratories, Inc., 317 

Rutledge Rd., Fletcher, NC 28732, 

828–650–0409

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 505–

727–6300/800–999–5227

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176, x276

Federal Register / Vol. 69, No. 23 / Wednesday, February 4, 2004 / Notices 5357

Southwest Laboratories, 2727 W. 

Baseline Rd., Tempe, AZ 85283, 602–

438–8507/800–279–0027

Sparrow Health System, Toxicology 

Testing Center, St. Lawrence Campus, 

1210 W. Saginaw, Lansing, MI 48915, 

517–377–0520, (Formerly: St. 

Lawrence Hospital & Healthcare 

System) 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272–

7052

Sure-Test Laboratories, Inc., 2900 Broad 

Ave., Memphis, TN 38112, 901–474–

6026

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755–

5235, 301–677–7085

Anna Marsh, 

Acting Executive Officer, SAMHSA.

[FR Doc. 04–2249 Filed 2–3–04; 8:45 am] 

BILLING CODE 4160–20–P

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[USCG–2003–16327] 

Information Collections Under Review 

by the Office of Management and 

Budget (OMB): 1625–0074, 1625–0041, 

1625–0064, 1625–0049, and 1625–0007

AGENCY: Coast Guard, DHS.

ACTION: Request for comments.

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, this 

request for comments announces that 

the Coast Guard has forwarded five 

information collection reports (ICRs) to 

the Office of Information and Regulatory 

Affairs (OIRA) of the OMB for review 

and comment. These ICRs are: (1) 1625–

0074, Direct User Fees for Inspection or 

Examination of U.S. and Foreign 

Commercial Vessels; (2) 1625–0041, 

International Oil Pollution Prevention 

Certificate; (3) 1625–0064, Plan 

Approval and Records for Subdivision 

and Stability Regulations — Title 46 

CFR Subchapter S; (4) 1625–0049, 

Waterfront Facilities Handling Liquefied 

Natural Gas (LNG) and Liquefied 

Hazardous Gas (LHG); and (5) 1625–

0007, Characteristics of Liquid 

Chemicals Proposed for Bulk Water 

Movement. Our ICRs describe the 

information we seek to collect from the 

public. Review and comment by OIRA 

ensure that we impose only paperwork 

burdens commensurate with our 

performance of duties.

DATES: Please submit comments on or 

before March 5, 2004.

ADDRESSES: To make sure that your 

comments and related material do not 

enter the docket [USCG–2003–16327] 

more than once, please submit them by 

only one of the following means: 

(1)(a) By mail to the Docket 

Management Facility, U.S. Department 

of Transportation, room PL–401, 400 

Seventh Street SW., Washington, DC 

20590–0001. 

(b) By mail to OIRA, 725 17th Street 

NW., Washington, DC 20503, to the 

attention of the Desk Officer for the 

Coast Guard. Caution: Because of recent 

delays in the delivery of mail, your 

comments may reach the Facility more 

quickly if you choose one of the means 

described below. 

(2)(a) By delivery to room PL–401 at 

the address given in paragraph (1)(a) 

above, between 9 a.m. and 5 p.m., 

Monday through Friday, except Federal 

holidays. The telephone number is 202–

366–9329. 

(b) By delivery to OIRA, at the address 

given in paragraph (1)(b) above, to the 

attention of the Desk Officer for the 

Coast Guard. 

(3) By fax to (a) the Facility at 202–

493–2251 and 

(b) OIRA at 202–395–5806, or e-mail 

to OIRA at oira_docket@omb.eop.gov

attention: Desk Officer for the Coast 

Guard. 

(4)(a) Electronically through the Web 

Site for the Docket Management System 

at http://dms.dot.gov.

(b) OIRA does not have a website on 

which you can post your comments. 

The Facility maintains the public 

docket for this notice. Comments and 

material received from the public, as 

well as documents mentioned in this 

notice as being available in the docket, 

will become part of this docket and will 

be available for inspection or copying at 

room PL–401 (Plaza level), 400 Seventh 

Street SW., Washington, DC, between 9 

a.m. and 5 p.m., Monday through 

Friday, except Federal holidays. You 

may also find this docket on the Internet 

at http://dms.dot.gov.

Copies of the complete ICRs are 

available for inspection and copying in 

public dockets. They are available in 

docket USCG–2003–16327 Docket 

Management Facility between 10 a.m. 

and 5 p.m., Monday through Friday, 

except Federal holidays; for inspection 

and printing on the internet at http://

dms.dot.gov; and for inspection from the 

Commandant at CG–611, U.S. Coast 

Guard, room 6106, 2100 Second Street 

SW., Washington, DC, between 10 a.m. 

and 4 p.m., Monday through Friday, 

except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Ms. 

Bernice Parker-Jones, Office of 

Information Management, 202–267–

2326, for questions on this document; 

Ms. Andrea M. Jenkins, Program 

Manager, U.S. Department of 

Transportation, 202–366–0271, for 

questions on the docket.

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

We encourage you to participate in 

this request for comment by submitting 

comments and related materials. We 

will post all comments received, 

without change, to http://dms.dot.gov,

and they will include any personal 

information you have provided. We 

have an agreement with DOT to use the 

Docket Management Facility. Please see 

the paragraph on DOT’s ‘‘Privacy Act’’

below. 

Submitting comments: If you submit a 

comment, please include your name and 

address, identify the docket number for 

this request for comment [USCG–2003–

16327], indicate the specific section of 

this document to which each comment 

applies, and give the reason for each 

comment. You may submit your 

comments and material by electronic 

means, mail, fax, or delivery to the 

Docket Management Facility at the 

address under ADDRESSES; but please 

submit your comments and material by 

only one means. If you submit them by 

mail or delivery, submit them in an 

unbound format, no larger than 81⁄2 by 

11 inches, suitable for copying and 

electronic filing. If you submit them by 

mail and would like to know that they 

reached the Facility, please enclose a 

stamped, self-addressed postcard or 

envelope. We will consider all 

comments and material received during 

the comment period. We may attempt to 

adjust paperwork burdens to be more 

commensurate with our performance of 

duties in view of them. 

Viewing comments and documents:

To view comments, as well as 

documents mentioned in this preamble 

as being available in the docket, go to 

http://dms.dot.gov at any time and 

conduct a simple search using the 

docket number. You may also visit the 

Docket Management Facility in room 

PL–401 on the Plaza level of the Nassif 

Building, 400 Seventh Street SW., 

Washington, DC, between 9 a.m. and 5